Current label answer
The Wegovy percentage covers a group of local reactions
The manufacturer Wegovy label has an effective date of June 18, 2026. In adult weight-reduction trials, 1.4% of Wegovy-treated patients and 1% of placebo-treated patients experienced grouped injection-site reactions. The listed examples were injection-site itching, redness, inflammation, firmness, and irritation. The label does not publish a separate rate for a red spot, itch, lump, swelling, pain, burning, or delayed reaction, and it does not establish one expected size or duration.
- Keep 1.4% and 1% tied to the adult Wegovy weight-reduction trials and the grouped label category.
- Do not say that every participant counted in the category had the same appearance, severity, onset, cause, or course.
- A group-level trial percentage cannot diagnose one reaction or determine whether it reflects irritation, allergy, infection, bleeding, tissue injury, or another cause.
Route and product identity
Only the injectable Wegovy presentation has an injection site
Current Wegovy labeling includes both subcutaneous injection and once-daily oral tablets. A local injection-site symptom therefore must be matched to an injectable presentation rather than to the brand name alone. For Wegovy injection, record the package and device details, refill information, labeled body area, storage history, and whether the skin or anything touching it changed. Follow the instructions supplied with the exact package; this symptom guide is not a substitute for the product instructions or individualized training.
- Confirm the name, route, presentation, manufacturer label, refill or lot information, storage history, and prescribing and dispensing contacts.
- Note any new cleanser, alcohol prep, adhesive, bandage, lotion, topical medicine, clothing friction, caregiver help, or pre-existing skin problem near the site.
- Do not repeat an injection, change the prescribed schedule, improvise device steps, or use an online pen or syringe workaround because a treatment felt different or left a skin mark.
Local versus whole-body symptoms
A local mark and a serious allergic reaction are different safety questions
A red, itchy, firm, or irritated area near an injection is not automatically the same as a serious hypersensitivity reaction. However, the current Wegovy label reports serious hypersensitivity reactions such as anaphylaxis and angioedema. Facial, lip, tongue, or throat swelling; trouble breathing or swallowing; widespread hives; wheezing; fainting; severe confusion; or a rapidly developing whole-body reaction can require emergency care. A photo, reaction diameter, or online symptom list cannot rule out serious allergy.
- Call emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, or a rapidly worsening widespread reaction.
- Do not use another treatment as a test or start an unreviewed antihistamine, steroid, or other medicine simply to stay on schedule.
- Tell the care team about prior medication allergy, anaphylaxis, angioedema, eczema, adhesive reactions, and any new medicine, supplement, or topical exposure.
Trend and local warning signs
Border, warmth, pain, drainage, and fever matter more than one snapshot
Useful details include how soon the reaction appeared, its approximate size and location, whether the border is stable or expanding, and whether itching, redness, warmth, pain, firmness, swelling, bruising, drainage, red streaks, fever, blistering, darkening, numbness, or skin breakdown is present. Rapid spread, increasing warmth or pain, pus, streaking, fever, or feeling acutely unwell can require prompt in-person assessment for infection or another local complication. Severe or disproportionate pain, color change, blistering, numbness, or skin breakdown also should not be managed through a seller chat or forum.
- Use dated photos with a size reference only when the care team requests them; lighting and skin tone can make color alone misleading.
- Seek prompt local assessment for rapid spread, severe or escalating pain, pus, red streaks, fever or chills, blistering, darkening, numbness, or skin breakdown.
- Contact the prescriber for a reaction that persists, returns after injections, enlarges, worsens, becomes unusually painful, or limits treatment even when emergency features are absent.
Skin and site review
Use healthy skin and the exact package instructions
The current Wegovy injection label lists the abdomen, thigh, or upper arm and directs site rotation. MedlinePlus semaglutide injection information independently lists the upper arm, thigh, or stomach area and says to use a different site for each injection. General MedlinePlus subcutaneous-injection guidance says the selected area should not already have redness, swelling, scarring, bruising, or other skin or tissue damage. These points support avoiding an affected area and requesting product-specific guidance; they do not justify improvised device steps or a universal home-treatment plan.
- Report whether the skin was already red, swollen, bruised, scarred, hardened, irritated, recently shaved, or affected by eczema, infection, or another condition.
- Ask the prescriber, pharmacist, or manufacturer support team to review unclear device, package, storage, or site-rotation questions before another treatment decision.
- Do not squeeze, puncture, vigorously massage, inject into, or cover a concerning area with leftover prescription creams or an unreviewed home remedy.
Compounded-product boundary
A compounded semaglutide preparation does not inherit the Wegovy rate
Wegovy is an FDA-approved finished semaglutide product with product-specific labeling. A patient-specific compounded semaglutide preparation is not an FDA-approved finished drug product and can differ in concentration, inactive ingredients, presentation, container, supplies, storage instructions, and beyond-use date. The Wegovy trial percentage cannot validate a compounded preparation, establish its local-reaction rate, or explain why one person developed a skin reaction after a compounded injection.
- Confirm the active ingredient, route, concentration, dispensing pharmacy, patient label, supplies, storage history, refill details, and adverse-event contact.
- Ask the dispensing pharmacy about a changed label, concentration, inactive ingredient, damaged package, warm shipment, particles, discoloration, or uncertain storage before another use decision.
- Avoid research-use vials, counterfeit pens or tablets, unlabeled mixtures, copied syringe conversions, and sellers that bypass prescription-first clinician review.